BioPorto A/S (FRA:2P4)

Market Cap	63.64M -25.5%
Revenue (ttm)	4.90M +4.7%
Net Income	-11.62M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	0.1130
Previous Close	0.1146
Day's Range	0.1130 - 0.1130
52-Week Range	0.1130 - 0.1982
Beta	n/a
RSI	34.47
Earnings Date	Mar 26, 2026

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1917
• Employees: 48
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2P4

Financial Performance

In 2024, BioPorto's revenue was 36.24 million, an increase of 17.07% compared to the previous year's 30.96 million. Losses were -68.24 million, 21.2% more than in 2023.

Financial numbers in DKK